Popular Weight Loss Drugs May Offer New Heart Attack Treatment Option

A groundbreaking study published this week in Nature Communications reveals that a widely used class of weight-loss medications may provide significant protection against life-threatening heart complications following a heart attack.

The research, led by scientists from the University of Bristol and University College London, has identified a previously unknown biological signaling pathway connecting the brain, gut, and heart. This discovery helps explain how GLP-1 drugs—medications that mimic the hormone glucagon-like peptide-1—can protect heart tissue from a dangerous condition known as “no-reflow.”

“In nearly half of all heart attack patients, tiny blood vessels within the heart muscle remain narrowed, even after the main artery is cleared during emergency medical treatment,” explained Dr. Svetlana Mastitskaya, the study’s lead author and senior lecturer at Bristol Medical School. “This results in a complication called ‘no-reflow,’ where blood is unable to reach certain parts of the heart tissue.”

This lack of blood flow to portions of the heart significantly increases a patient’s risk of developing heart failure or dying within a year after their heart attack. The new research suggests that GLP-1 medications could potentially prevent this dangerous complication.

The study details a complex biological mechanism. When GLP-1 is released naturally in the gut or administered as a medication, it triggers a signal to the brain, which then sends instructions to the heart. These signals activate special potassium channels in cells called pericytes, which surround the small blood vessels in heart tissue. When these channels open, the pericytes relax, allowing the tiny capillaries to widen and improve blood flow to the heart muscle.

Using animal models and advanced cellular imaging techniques, the researchers tracked exactly how GLP-1 interacts with heart tissue. To confirm the role of the potassium channels, they conducted experiments where these channels were removed—finding that without them, the drugs no longer provided heart protection. This confirmed that these channels play a crucial role in the protective mechanism.

The findings carry significant clinical implications. GLP-1 medications—already widely prescribed for type 2 diabetes and obesity management under brand names like Ozempic, Wegovy, Mounjaro, and Zepbound—could potentially be repurposed as emergency treatments during or immediately following a heart attack to reduce tissue damage and improve outcomes.

“This research opens up an exciting new avenue for heart attack treatment,” said a cardiovascular specialist not involved in the study. “With millions of people worldwide already using these medications for metabolic conditions, understanding their cardiac benefits could rapidly translate to clinical applications.”

The pharmaceutical market for GLP-1 drugs has exploded in recent years, primarily due to their effectiveness in weight management. Global sales of these medications reached approximately $24 billion in 2023 and are projected to exceed $100 billion by 2030, according to market analysts. This new research could potentially expand their application into acute cardiac care, further increasing their medical significance.

The researchers acknowledge several limitations to their findings. Most importantly, the study relied primarily on animal models. Clinical trials will be necessary to determine whether the brain-gut-heart pathway operates with the same timing and efficacy in humans. Additionally, while the study highlights the drug’s potential immediate benefits during a heart attack, it does not establish whether long-term use of these medications provides pre-existing protection for patients who might experience a cardiac event.

The British Heart Foundation provided primary funding for this research, which represents a significant step toward better understanding how existing medications might be repurposed to address one of the most dangerous complications of heart attacks.

As heart disease remains the leading cause of death globally, this discovery could potentially improve outcomes for millions of patients worldwide if the findings translate successfully to human clinical applications.